학술논문
C型肝炎病毒抗體快篩試劑的運用 / Rapid diagnostic tests for detection of antibodies to hepatitis C virus
Document Type
Article
Author
楊雯雯 / Wen-Wen Yang; 吳慧敏 / Grace Hui-Min Wu; 劉嘉玲 / Chia-Ling Liu; 鄭國本 / Kuo-Pen Cheng; 余明隆 / Ming-Lung Yu; 蒲若芳 / Raoh-Fang Pwu; 盧勝男 / Sheng-Nan Lu; 簡榮南 / Rong-Nan Chien
Source
台灣公共衛生雜誌 / Taiwan Journal of Public Health. Vol. 42 Issue 6, p594-611. 18 p.
Subject
Language
繁體中文
英文
英文
ISSN
1023-2141
Abstract
Most patients with chronic hepatitis C often remain asymptomatic or experience nonspecific symptoms for decades, and by the time symptoms manifest, the disease has deteriorated to life-threatening stages such as cirrhosis or liver cancer. Early detection of hepatitis C virus (HCV) infection is crucial for preventing and managing subsequent complications. The conventional two-step diagnostic process, involving initial enzyme immunoassay testing for HCV antibodies (anti- HCV) followed by nucleic acid testing in the laboratory to confirm the presence of HCV, presents a significant challenge in the discovery and diagnosis of HCV virus infection. In addition to traditional laboratory-based serum antibody testing, the World Health Organization recommends the use of rapid diagnostic tests (RDTs) as one of the methods for analyzing anti-HCV antibodies, with the potential to improve access and linkage to care and treatment. Since 2020, the studies have shown that both the specificity and sensitivity of the anti-HCV RDTs have been improved. Three anti-HCV RDTs in Taiwan have received market approval, each demonstrating a sensitivity and specificity of at least 92.8% and 92.6%, respectively, as indicated by literature reviews. This article collects and summarizes existing literature on the diagnostic performance of anti-HCV RDTs and their implementation scenarios. It aims to enhance awareness across various sectors regarding the utility of anti-HCV RDTs and to discuss their potential applications in accelerating hepatitis C elimination efforts in Taiwan.